Evaluation of Chronic Liver Disease Condition and Transplant Prognosis Assisted by Eye Biological Parameters
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Zizheng Cao, M.D.
- Phone Number: +86-13201672078
- Email: caozzh@mail2.sysu.edu.cn
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Recruiting
- Zhongshan Ophthalmic Center, Sun Yat-sen University
-
Contact:
- Haotian Lin, M.D., Ph.D
- Phone Number: +86-13802793086
- Email: linht5@mail.sysu.edu
-
Contact:
- Xiaohang Wu, M.D., Ph.D
- Phone Number: +86-15913177657
- Email: wxhang@mail2.sysu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age greater than or equal to 18 years old;
- Late stage liver disease patients waiting for liver transplantation treatment, as well as patients with varying degrees of cirrhosis;
- Can collect complete basic demographic information, liver function blood test indicators, liver pathology and imaging examination results;
- Can cooperate with eye OCT, OCTA and other examinations, and obtain qualified examination parameters;
- Voluntarily follow the clinical trial protocol and sign the informed consent form.
Exclusion Criteria:
- History of other organ transplant surgeries;
- History of intraocular laser treatment, medication injection, and surgery;
- History of high myopia, glaucoma, and retinal choroidal related eye diseases;
- History of major systemic diseases other than liver disease;
- Individuals whose overall body and eye conditions cannot cooperate with eye examinations.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
preoperative group
Registered liver transplant patients from preoperative to postoperative follow-up
|
Various ophthalmic examination modalities, including slit lamp photography, fundus photography, optical coherence tomography imaging and optical coherence tomography angiography, etc.
Various general condition examination, including blood pressure measurement, blood glucose testing, blood routine examination, coagulation function test, liver function test, etc.
|
|
Simple postoperative group
Follow up from after liver transplantation
|
Various ophthalmic examination modalities, including slit lamp photography, fundus photography, optical coherence tomography imaging and optical coherence tomography angiography, etc.
Various general condition examination, including blood pressure measurement, blood glucose testing, blood routine examination, coagulation function test, liver function test, etc.
|
|
Healthy control group
Healthy individuals without liver disease
|
Various ophthalmic examination modalities, including slit lamp photography, fundus photography, optical coherence tomography imaging and optical coherence tomography angiography, etc.
Various general condition examination, including blood pressure measurement, blood glucose testing, blood routine examination, coagulation function test, liver function test, etc.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The performance of predicting the prognosis of liver transplantation
Time Frame: 1 week and 1 year after liver transplantation
|
Based on the outcomes of early graft dysfunction and 1-year graft survival rate, the area under the receiver operating characteristic curve, specificity, and sensitivity of the model
|
1 week and 1 year after liver transplantation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The performance of the model in assessing the severity of liver disease
Time Frame: 1 year
|
The confusion matrix of the model based on the MELD score results
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2021KYPJ148
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.